BioCryst Pharmaceuticals Inc (BCRX)
5.34
+0.24
(+4.71%)
USD |
NASDAQ |
May 09, 16:00
5.63
+0.29
(+5.43%)
After-Hours: 20:00
BioCryst Pharmaceuticals Revenue (Quarterly): 92.76M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 92.76M |
| December 31, 2023 | 93.40M |
| September 30, 2023 | 86.74M |
| June 30, 2023 | 82.49M |
| March 31, 2023 | 68.78M |
| December 31, 2022 | 79.54M |
| September 30, 2022 | 75.83M |
| June 30, 2022 | 65.53M |
| March 31, 2022 | 49.92M |
| December 31, 2021 | 47.16M |
| September 30, 2021 | 40.99M |
| June 30, 2021 | 49.96M |
| March 31, 2021 | 19.06M |
| December 31, 2020 | 4.016M |
| September 30, 2020 | 6.102M |
| June 30, 2020 | 2.871M |
| March 31, 2020 | 4.823M |
| December 31, 2019 | 39.72M |
| September 30, 2019 | 1.775M |
| June 30, 2019 | 1.448M |
| March 31, 2019 | 5.887M |
| December 31, 2018 | 2.729M |
| September 30, 2018 | 1.454M |
| June 30, 2018 | 12.49M |
| March 31, 2018 | 3.976M |
| Date | Value |
|---|---|
| December 31, 2017 | 3.89M |
| September 30, 2017 | 8.76M |
| June 30, 2017 | 3.099M |
| March 31, 2017 | 9.437M |
| December 31, 2016 | 8.983M |
| September 30, 2016 | 7.763M |
| June 30, 2016 | 4.787M |
| March 31, 2016 | 4.82M |
| December 31, 2015 | 4.602M |
| September 30, 2015 | 10.99M |
| June 30, 2015 | 25.84M |
| March 31, 2015 | 6.826M |
| December 31, 2014 | 5.446M |
| September 30, 2014 | 3.238M |
| June 30, 2014 | 1.466M |
| March 31, 2014 | 3.458M |
| December 31, 2013 | 10.57M |
| September 30, 2013 | 2.389M |
| June 30, 2013 | 0.821M |
| March 31, 2013 | 3.554M |
| December 31, 2012 | 4.101M |
| September 30, 2012 | 5.761M |
| June 30, 2012 | 4.21M |
| March 31, 2012 | 12.22M |
| December 31, 2011 | 5.224M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.448M
Minimum
Jun 2019
93.40M
Maximum
Dec 2023
45.65M
Average
48.54M
Median
Revenue (Quarterly) Benchmarks
| Integra Lifesciences Holdings Corp | 368.87M |
| Krystal Biotech Inc | 45.25M |
| AIM ImmunoTech Inc | 0.065M |
| Protalix BioTherapeutics Inc | 10.49M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -35.38M |
| Total Expenses (Quarterly) | 107.25M |
| EPS Diluted (Quarterly) | -0.17 |
| Enterprise Value | 1.529B |
| Gross Profit Margin (Quarterly) | 98.50% |
| Profit Margin (Quarterly) | -38.14% |
| Earnings Yield | -20.04% |
| Normalized Earnings Yield | -17.70 |